You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Therapy Areas: Cardiovascular
Nuwellis completes Rendiatech acquisition
Login
Username:

Password:


Related Headlines

Circio and AaviGen partner to develop next-generation gene therapies for heart disease

Eli Lilly reports positive Phase 1b results for VERVE-102

Bayer's KERENDIA receives FDA priority review for type 1 diabetes and kidney disease treatment

Artivion completes acquisition of Endospan following FDA approval of NEXUS Aortic Arch System

AstraZeneca wins US approval for Baxfendy as first aldosterone synthase inhibitor for hypertension

GSK's Arexvy gains expanded approval in Japan for at-risk adults aged 18-49

Tenaya Therapeutics reports interim RIDGE-1 data showing reduced arrhythmia burden with TN-401

AnaCardio reports Phase 1b/2a data showing cardiac function gains with AC01

Veradermics reports positive Phase 2/3 results for oral VDPHL01 in pattern hair loss treatment

Thryv Therapeutics doses first patients in Wave II clinical study for Long QT Syndrome; THRV-1268 receives FDA Fast Track Designation

Ondine Biomedical abstracts selected for 2026 World Congress on Infectious Diseases

Philips secures FDA clearance for Spectral CT Verida system

Eli Lilly launches Foundayo weight‑loss pill in the US

Lilly's Foundayo (orforglipron) weight loss pill gains US FDA approval

Hengrui Pharma and Braveheart Bio report positive Phase 2 results for HRS/BHB-1893 in oHCM

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026